Search

everythinglearnresearchcommunity

for

Search:↓

CD28 is a promising target for treating alopecia areata with belatacept.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

CD271 is crucial for maintaining healthy skin and preventing inflammation.

Targeting CD169+ skin macrophages may help treat psoriasis.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.

Blocking certain immune signals can reduce skin damage from radiation therapy.

CD27 and IL-35 can help diagnose alopecia areata linked to bacterial infections.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

TEDAR is crucial for skin cell differentiation and barrier formation.

CD44 signaling can help heal wounds without scars.

CD117 and platelet-derived growth factor receptor α may play a role in alopecia areata.

Retinoic acid production and signaling in hair follicles are regulated by location and timing, affecting hair growth and cycling.

Double-stranded RNA helps regenerate hair follicles by increasing retinoic acid production and signaling.

GPRC5D is linked to the formation of hair, nails, and certain tongue areas.

Scientists found a new type of skin cell that could help with skin repair and these cells work better with a certain protein.

No CD44 in alopecia areata, present in normal and androgenetic alopecia.

Retinoic acid can either maintain stem cells or make them specialize, depending on the cell type.

The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

The rs231775 genetic variant is linked to a higher risk and severity of Alopecia Areata in males.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.

FCER1A and RGS1 may help diagnose and treat systemic lupus erythematosus.

Belatacept may be a promising treatment for alopecia areata.

RAR-gamma 1 is important for normal skin maintenance and differentiation.

The treatment was not recommended due to limited effectiveness and significant side effects.